GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (OTCPK:HSTO) » Definitions » Total Current Liabilities

Histogen (Histogen) Total Current Liabilities : $1.35 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Histogen Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Histogen's total current liabilities for the quarter that ended in Sep. 2023 was $1.35

Histogen Total Current Liabilities Historical Data

The historical data trend for Histogen's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Total Current Liabilities Chart

Histogen Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Current Liabilities
1.38 2.79 2.33 1.23

Histogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.40 1.23 1.34 0.97 1.35

Histogen Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Histogen's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.808+0.247
+Other Current Liabilities+Current Deferred Liabilities
=0.16+0.019
=1.23

Histogen's Total Current Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.542+0
+Other Current Liabilities+Current Deferred Liabilities
=0.787+0.019
=1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Histogen Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Histogen's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Histogen (Histogen) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (OTCPK:HSTO) » Definitions » Total Current Liabilities
Comparable Companies
GLMD BLCM NBY CYTO RUBY AGTX CFRX ADTX NTRR ISCO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
Website
https://www.histogen.com
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
Executives
Joyce Reyes officer: See Remarks 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Richard W Pascoe director, officer: See Remarks C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Rochelle Fuhrmann director C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Susan Richards Windham-bannister director 78 BLANCHARD ROAD, BURLINGTON MA 01803
Moya Daniels officer: See Remarks 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Susan A. Knudson officer: See Remarks 9191 TOWNE CENTRE DRIVE, SUITE 400, SAN DIEGO CA 92121
Jonathan Jackson director, 10 percent owner C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Gail K Naughton officer: See Remarks C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Hugh Crean director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Stephen Chang director 12912 CAMINO DEL VALLE, POWAY CA 92064
Brian Satz director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Yizhuo Zhang director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Martin Latterich officer: See Remarks C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Steven J Mento director C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Keith W Marshall officer: EVP, COO & CFO C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127

Histogen (Histogen) Headlines

From GuruFocus

Histogen to Explore Strategic Alternatives

By Marketwired • 07-05-2023

Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer

By Stock market mentor Stock market mentor • 01-03-2023

Histogen to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews • 06-26-2022

Histogen to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews • 06-06-2022

Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

By GuruFocusNews GuruFocusNews • 05-22-2022

Histogen Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews • 06-21-2022

Histogen to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews • 05-27-2022

Histogen Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews • 06-01-2022

Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

By PurpleRose PurpleRose • 07-11-2022

Histogen Announces Closing of $4.75 Million Private Placement

By GuruFocusNews GuruFocusNews • 03-25-2022